CLINICAL TRIAL

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2024-10-23
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Imperial College London

Watch author

Topics and keywords

psilocybin Depression Mechanism of Action Receptor Pharmacology Clinical Trial Clinical Trial Depressive Disorder Major Psilocybin + Placebo Psilocybin + Escitalopram COMPLETED

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

Bibliographic context

Authors

Topics and keywords

Citation graph

Related papers